<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">


<!-- Mirrored from medicain.net/DUOC THU QUOC GIA/Cefalotin.htm by HTTrack Website Copier/3.x [XR&CO'2013], Tue, 25 Mar 2014 18:06:27 GMT -->
<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 11">
<meta name=Originator content="Microsoft Word 11">
<link rel=File-List href="filelist-108.xml.html" tppabs="http://www.vietstarse.com/duocthu/Documents/Cefalotin_files/filelist.xml">
<link rel=Edit-Time-Data href="javascript:if(confirm('http://www.vietstarse.com/duocthu/Documents/Cefalotin_files/editdata.mso  \n\nThis file was not retrieved by Teleport Pro, because the server reports that this file cannot be found.  \n\nDo you want to open it from the server?'))window.location='http://www.vietstarse.com/duocthu/Documents/Cefalotin_files/editdata.mso'" tppabs="http://www.vietstarse.com/duocthu/Documents/Cefalotin_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>CEFALOTIN</title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>VIETSTAR</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>lylv</o:LastAuthor>
  <o:Revision>5</o:Revision>
  <o:TotalTime>11</o:TotalTime>
  <o:Created>2006-08-08T14:03:00Z</o:Created>
  <o:LastSaved>2006-08-09T05:20:00Z</o:LastSaved>
  <o:Pages>3</o:Pages>
  <o:Words>1941</o:Words>
  <o:Characters>11069</o:Characters>
  <o:Company>VS</o:Company>
  <o:Lines>92</o:Lines>
  <o:Paragraphs>25</o:Paragraphs>
  <o:CharactersWithSpaces>12985</o:CharactersWithSpaces>
  <o:Version>11.5606</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:DoNotHyphenateCaps/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas>false</w:ValidateAgainstSchemas>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotUnderlineInvalidXML/>
  <w:Compatibility>
   <w:SelectEntireFieldWithStartOrEnd/>
   <w:UseWord2002TableStyleRules/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" LatentStyleCount="156">
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 0 0 0 415 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
@font-face
	{font-family:TahomaH;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-alt:Arial;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-font-kerning:0pt;}
h2
	{mso-style-next:Normal;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:9.0pt;
	font-family:Tahoma;}
h3
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-line-height-alt:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	layout-grid-mode:char;
	font-size:14.0pt;
	font-family:Tahoma;
	font-weight:normal;
	font-style:italic;}
h4
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:9.0pt;
	font-family:Tahoma;
	font-weight:normal;}
h5
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:5;
	font-size:9.0pt;
	font-family:Tahoma;}
h6
	{mso-style-next:Normal;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.3pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:6;
	font-size:9.0pt;
	font-family:Tahoma;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:7;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:8;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:9;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-noshow:yes;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	tab-stops:right 411.1pt;
	border:none;
	mso-border-bottom-alt:solid windowtext .5pt;
	padding:0in;
	mso-padding-alt:0in 0in 1.0pt 0in;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-noshow:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
span.MsoFootnoteReference
	{mso-style-noshow:yes;
	vertical-align:super;}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
span.MsoPageNumber
	{mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:Tahoma;
	mso-ascii-font-family:Tahoma;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:TahomaH;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:TahomaH;
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-2.0in;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:14.2pt;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-style:italic;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-14.15pt;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.4in;
	margin-bottom:0in;
	margin-left:.4in;
	margin-bottom:.0001pt;
	line-height:10.5pt;
	mso-line-height-rule:exactly;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-noshow:yes;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	background:navy;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.1, li.1, div.1
	{mso-style-name:1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.1nho, li.1nho, div.1nho
	{mso-style-name:1nho;
	margin-top:3.5pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.2, li.2, div.2
	{mso-style-name:2;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.3, li.3, div.3
	{mso-style-name:3;
	mso-style-parent:2;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.5, li.5, div.5
	{mso-style-name:5;
	mso-style-parent:2;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-style:italic;}
p.bai, li.bai, div.bai
	{mso-style-name:bai;
	mso-style-parent:"Heading 2";
	margin-top:25.0pt;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	text-align:center;
	line-height:10.4pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.BodyText21, li.BodyText21, div.BodyText21
	{mso-style-name:"Body Text 21";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-line-height-alt:10.5pt;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.cach0, li.cach0, div.cach0
	{mso-style-name:"cach0\,4";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.chucach, li.chucach, div.chucach
	{mso-style-name:chucach;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.normal1, li.normal1, div.normal1
	{mso-style-name:normal1;
	mso-style-parent:"cach0\,4";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:10.5pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	mso-style-parent:"Heading 2";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:48.2pt;
	text-align:justify;
	text-indent:-17.0pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	tab-stops:list 49.2pt;
	font-size:14.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1027"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US style='tab-interval:.5in'>

<div class=Section1>

<h1 align=center style='text-align:center;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:15.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>CEFALOTIN</span><span lang=DE style='font-size:
9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'><o:p></o:p></span></h1>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%;mso-outline-level:
1'><b><span lang=DE style='font-size:9.0pt;mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana;mso-ansi-language:DE'>Tên chung qu&#7889;c
t&#7871;: </span></b><span lang=DE style='font-size:9.0pt;mso-bidi-font-size:
14.0pt;line-height:150%;font-family:Verdana;mso-ansi-language:DE'>Cefalotin.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%;mso-outline-level:
1'><b><span lang=DE style='font-size:9.0pt;mso-bidi-font-size:14.0pt;
line-height:150%;font-family:Verdana;mso-ansi-language:DE'>Mã ATC:</span></b><span
lang=DE style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana;mso-ansi-language:DE'> J01D A03.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><b><span
lang=DE style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana;mso-ansi-language:DE'>Lo&#7841;i thu&#7889;c:</span></b><span
lang=DE style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana;mso-ansi-language:DE'> Thu&#7889;c tiêm kháng sinh nhóm
cephalosporin th&#7871; h&#7879; 1.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>D&#7841;ng thu&#7889;c và hàm l&#432;&#7907;ng<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Thu&#7889;c tiêm là d&#7841;ng cefalotin natri.
Li&#7873;u &#273;&#432;&#7907;c bi&#7875;u th&#7883; theo s&#7889; l&#432;&#7907;ng
t&#432;&#417;ng &#273;&#432;&#417;ng c&#7911;a cefalotin. 1,06 g cefalotin
natri t&#432;&#417;ng &#273;&#432;&#417;ng v&#7899;i 1 g cefalotin. 1 gam
cefalotin natri t&#432;&#417;ng &#7913;ng v&#7899;i 2,39 milimol natri.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>B&#7897;t vô khu&#7849;n pha tiêm: M&#7895;i l&#7885;
ch&#7913;a cefalotin natri t&#432;&#417;ng &#273;&#432;&#417;ng v&#7899;i 1 g
cefalotin và 30 mg natri bicarbonat, ho&#7863;c ch&#7913;a cefalotin natri
t&#432;&#417;ng &#273;&#432;&#417;ng v&#7899;i 2 g cefalotin và 60 mg natri
bicarbonat.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>D&#432;&#7907;c lý và c&#417; ch&#7871; tác d&#7909;ng<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Cefalotin là kháng sinh nhóm cephalosporin th&#7871;
h&#7879; 1, cefalotin có tác d&#7909;ng di&#7879;t khu&#7849;n b&#7857;ng cách
ng&#259;n c&#7843;n s&#7921; phát tri&#7875;n và phân chia vi khu&#7849;n do &#7913;c
ch&#7871; t&#7893;ng h&#7907;p vách t&#7871; bào vi khu&#7849;n. Cefalotin dùng
theo &#273;&#432;&#7901;ng tiêm, có ho&#7841;t tính m&#7841;nh trên các c&#7847;u
khu&#7849;n Gram d&#432;&#417;ng. Thu&#7889;c có tác d&#7909;ng t&#7889;t trên
các tr&#7921;c khu&#7849;n Gram d&#432;&#417;ng và có tác d&#7909;ng trung bình
trên các vi khu&#7849;n &#273;&#432;&#7901;ng ru&#7897;t Gram âm.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Các c&#7847;u khu&#7849;n Gram d&#432;&#417;ng nh&#7841;y
c&#7843;m bao g&#7891;m các ch&#7911;ng <i>Staphylococcus</i> ti&#7871;t và
không ti&#7871;t penicilinase. Tuy nhiên, các ch&#7911;ng <i>Staphylococcus</i>
kháng methicilin b&#7883; coi là luôn luôn kháng các cephalosporin. Ph&#7847;n
l&#7899;n các ch&#7911;ng <i>Streptococcus</i> nh&#7841;y c&#7843;m v&#7899;i
cefalotin, nh&#432;ng thu&#7889;c không có tác d&#7909;ng trên <i>Streptococcus
pneumoniae</i> kháng penicilin.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Các ch&#7911;ng <i>Enterococcus</i> c&#361;ng
th&#432;&#7901;ng kháng cefalotin.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Theo s&#7889; li&#7879;u ASTS (Antibiotics Sensitivity Testing
Studies) 1996, 1997. <i>S. aureus</i> có m&#7913;c nh&#7841;y c&#7843;m v&#7899;i
cefalotin t&#7915; 72 - 94% và m&#7913;c kháng t&#7915; 2 - 17%, <i>S.
epidermidis</i> có m&#7913;c nh&#7841;y c&#7843;m v&#7899;i cefalotin kho&#7843;ng
89% và kháng kho&#7843;ng 8%. Các ch&#7911;ng <i>Streptococcus</i> tan máu beta
nhóm A có m&#7913;c nh&#7841;y c&#7843;m v&#7899;i cefalotin t&#7915; 66 - 83%
và m&#7913;c kháng t&#7915; 8 - 18%. Tuy nhiên, m&#7913;c &#273;&#7897; nh&#7841;y
c&#7843;m c&#7911;a ch&#7911;ng này bi&#7875;u th&#7883; r&#7845;t khác nhau gi&#7919;a
các &#273;&#7883;a ph&#432;&#417;ng, khi so sánh gi&#7919;a các b&#7879;nh vi&#7879;n.
<i>Streptococcus pneumoniae</i> có m&#7913;c nh&#7841;y c&#7843;m v&#7899;i
cefalotin t&#7915; 70 - 99% v&#7899;i m&#7913;c kháng t&#7915; 1 - 17%.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><i><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Haemophilus influenzae </span></i><span style='font-size:9.0pt;
mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>th&#432;&#7901;ng
gi&#7843;m nh&#7841;y c&#7843;m<i>. Cefalotin </i>gi&#7843;m ho&#7841;t tính
trên m&#7897;t s&#7889;<i> Enterobacteriaceae, </i>bao g&#7891;m các ch&#7911;ng<i>
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis. Proteus indol </i>d&#432;&#417;ng
tính, m&#7897;t s&#7889;<i> Enterobacter </i>spp<i>., Pseudomonas aeruginosa</i>
<i>và Bacteroides </i>kháng<i> </i>cefalotin<i>.<o:p></o:p></i></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Theo s&#7889; li&#7879;u ASTS 1996, 1997, nh&#7919;ng ch&#7911;ng Gram
âm sau &#273;ây &#273;ã t&#259;ng kháng cefalotin:<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><i><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Escherichia coli</span></i><span style='font-size:9.0pt;mso-bidi-font-size:
14.0pt;line-height:150%;font-family:Verdana'> kháng cefalotin v&#7899;i t&#7927;
l&#7879; chung 53% trên toàn qu&#7889;c (78% &#7903; mi&#7873;n nam, 61% &#7903;
các t&#7881;nh mi&#7873;n trung và 46% &#7903; B&#7879;nh vi&#7879;n B&#7841;ch
mai). <i>Klebsiella pneumoniae</i> c&#361;ng kháng cefalotin v&#7899;i t&#7927;
l&#7879; chung 66% trên toàn qu&#7889;c. <i>Proteus mirabilis</i> c&#361;ng
kháng cefalotin v&#7899;i t&#7927; l&#7879; cao kho&#7843;ng 66% &#7903; B&#7879;nh
vi&#7879;n Vi&#7879;t Nam - Cuba Hà N&#7897;i (1994 - 1995) và 65% &#7903; B&#7879;nh
vi&#7879;n Ch&#7907; R&#7851;y TP. H&#7891; Chí Minh (1992 - 1996). <i>H.
influenzae</i> v&#7851;n còn khá nh&#7841;y c&#7843;m v&#7899;i cefalotin v&#7899;i
t&#7927; l&#7879; t&#7915; 88 - 90% và kháng v&#7899;i t&#7927; l&#7879; t&#7915;
5 - 10% &#7903; B&#7879;nh vi&#7879;n Thái Nguyên (1992 - 1994) và b&#7879;nh vi&#7879;n
huy&#7879;n Qu&#7843;ng X&#432;&#417;ng Thanh Hóa (1991 - 1993); t&#7927; l&#7879;
kháng c&#7911;a ch&#7911;ng này t&#259;ng lên &#273;&#7871;n 18% &#7903; B&#7879;nh
vi&#7879;n Trung &#432;&#417;ng Hu&#7871; <br>
(1988 - 1991) và 22% &#7903; B&#7879;nh vi&#7879;n &#273;a khoa Yên Bái (1993 -
1995).<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Do tình hình kháng kháng sinh &#273;ã nói &#7903; trên,
Ch&#432;&#417;ng trình ASTS &#273;ã khuy&#7871;n cáo vi&#7879;c &#273;i&#7873;u
tr&#7883; các b&#7879;nh nhi&#7877;m khu&#7849;n ph&#7843;i d&#7921;a vào kháng
sinh &#273;&#7891; c&#7911;a t&#7915;ng ch&#7911;ng và ph&#7843;i dùng ph&#7889;i
h&#7907;p các kháng sinh &#273;&#7875; có th&#7875; ng&#259;n c&#7843;n
&#273;&#432;&#7907;c s&#7921; phát tri&#7875;n tính kháng thu&#7889;c c&#7911;a
vi khu&#7849;n.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>N&#7891;ng &#273;&#7897; &#7913;c ch&#7871; t&#7889;i thi&#7875;u
(MIC) c&#7911;a cefalotin &#273;&#7889;i v&#7899;i các c&#7847;u khu&#7849;n Gram
d&#432;&#417;ng nh&#7841;y c&#7843;m n&#7857;m trong kho&#7843;ng t&#7915; 0,1
- 1 microgam/ml. Ph&#7847;n l&#7899;n các vi khu&#7849;n Gram âm nh&#7841;y c&#7843;m
th&#432;&#7901;ng c&#7847;n ph&#7843;i có n&#7891;ng &#273;&#7897; t&#7915; 1
&#273;&#7871;n 16 microgam/ml.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%;mso-outline-level:
1'><i><span style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana'>D&#432;&#7907;c &#273;&#7897;ng h&#7885;c<o:p></o:p></span></i></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Cefalotin &#273;&#432;&#7907;c h&#7845;p thu kém &#7903; &#273;&#432;&#7901;ng
tiêu hóa, nên ph&#7843;i tiêm. Sau khi tiêm b&#7855;p các li&#7873;u 0,5 g và 1
g, trong vòng 30 phút s&#7869; &#273;&#7841;t &#273;&#432;&#7907;c n&#7891;ng
&#273;&#7897; &#273;&#7881;nh huy&#7871;t t&#432;&#417;ng t&#432;&#417;ng &#7913;ng
là 10 microgam và 20 microgam/ml. Tiêm t&#297;nh m&#7841;ch li&#7873;u 1 g s&#7869;
có n&#7891;ng &#273;&#7897; &#273;&#7881;nh huy&#7871;t t&#432;&#417;ng 30
microgam/ml sau 15 phút. Tiêm truy&#7873;n liên t&#7909;c 500 mg/gi&#7901; s&#7869;
có n&#7891;ng &#273;&#7897; &#273;&#7881;nh huy&#7871;t t&#432;&#417;ng t&#7915;
14 &#273;&#7871;n 20 microgam/ml. Truy&#7873;n t&#297;nh m&#7841;ch li&#7873;u
2 g trong 30 phút, n&#7891;ng &#273;&#7897; &#273;&#7881;nh huy&#7871;t
t&#432;&#417;ng kho&#7843;ng 90 microgam/ml trong vòng 30 phút sau khi truy&#7873;n.
Tiêm truy&#7873;n có hi&#7879;u qu&#7843; h&#417;n tiêm b&#7855;p vì quan tr&#7885;ng
là n&#7891;ng &#273;&#7897; &#273;&#7881;nh &#273;&#7841;t &#273;&#432;&#7907;c
cao h&#417;n n&#7891;ng &#273;&#7897; t&#7889;i thi&#7875;u &#7913;c ch&#7871;
vi khu&#7849;n.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Cefalotin phân b&#7889; r&#7897;ng kh&#7855;p trong các mô và d&#7883;ch
c&#7911;a c&#417; th&#7875;, tr&#7915; não và d&#7883;ch não t&#7911;y có n&#7891;ng
&#273;&#7897; th&#7845;p và không th&#7875; d&#7921; &#273;oán &#273;&#432;&#7907;c.
Th&#7875; tích phân b&#7889; c&#7911;a cefalotin là 18 lít/1,73 m<sup>2</sup>
di&#7879;n tích c&#417; th&#7875;. Cefalotin &#273;&#7841;t n&#7891;ng &#273;&#7897;
có th&#7875; &#273;o &#273;&#432;&#7907;c trong d&#7883;ch màng ph&#7893;i,
nhãn phòng, m&#7853;t, kh&#7899;p và mô x&#432;&#417;ng. Cefalotin qua hàng rào
nhau thai vào tu&#7847;n hoàn thai nhi và có n&#7891;ng &#273;&#7897; th&#7845;p
trong s&#7919;a m&#7865;. N&#7917;a &#273;&#7901;i trong huy&#7871;t
t&#432;&#417;ng dao &#273;&#7897;ng t&#7915; 30 &#273;&#7871;n 50 phút,
nh&#432;ng có th&#7875; kéo dài h&#417;n &#7903; ng&#432;&#7901;i suy th&#7853;n,
nh&#7845;t là &#273;&#7889;i v&#7899;i ch&#7845;t chuy&#7875;n hóa. Kho&#7843;ng
70% cefalotin trong tu&#7847;n hoàn g&#7855;n k&#7871;t v&#7899;i protein huy&#7871;t
t&#432;&#417;ng.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Kho&#7843;ng 20 - 30% cefalotin nhanh chóng b&#7883; kh&#7917; acetyl
trong gan và kho&#7843;ng 60 - 70% li&#7873;u dùng &#273;&#432;&#7907;c bài ti&#7871;t
trong n&#432;&#7899;c ti&#7875;u qua &#7889;ng th&#7853;n trong 6 gi&#7901;
d&#432;&#7899;i d&#7841;ng cefalotin và ch&#7845;t chuy&#7875;n hóa
desacetylcefalotin t&#432;&#417;ng &#273;&#7889;i không ho&#7841;t tính. Sau
khi tiêm b&#7855;p các li&#7873;u 0,5 và 1 g, cefalotin có n&#7891;ng &#273;&#7897;
t&#432;&#417;ng &#7913;ng cao trong n&#432;&#7899;c ti&#7875;u là 0,8 mg và 2,5
mg/ml. Probenecid ng&#259;n ch&#7863;n s&#7921; bài ti&#7871;t c&#7911;a
cefalotin &#7903; th&#7853;n. Cefalotin bài ti&#7871;t &#7903; m&#7853;t v&#7899;i
s&#7889; l&#432;&#7907;ng r&#7845;t ít.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ch&#7881;
&#273;&#7883;nh<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Cefalotin &#273;&#432;&#7907;c coi là thu&#7889;c l&#7921;a ch&#7885;n
th&#7913; hai &#273;&#7875; &#273;i&#7873;u tr&#7883; các nhi&#7877;m khu&#7849;n
có bi&#7871;n ch&#7913;ng. Th&#432;&#7901;ng &#273;&#432;&#7907;c dùng &#273;&#7875;
&#273;i&#7873;u tr&#7883; thay th&#7871; penicilin, trong các nhi&#7877;m khu&#7849;n
do c&#7847;u khu&#7849;n Gram d&#432;&#417;ng và tr&#7921;c khu&#7849;n Gram
d&#432;&#417;ng nh&#7841;y c&#7843;m.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Cefalotin &#273;&#432;&#7907;c ch&#7881; &#273;&#7883;nh trong nhi&#7877;m
khu&#7849;n huy&#7871;t, viêm màng trong tim, viêm x&#432;&#417;ng - t&#7911;y
và các th&#7875; nhi&#7877;m khu&#7849;n n&#7863;ng khác.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Các ch&#7881; &#273;&#7883;nh khác: Nhi&#7877;m khu&#7849;n
&#273;&#432;&#7901;ng ti&#7871;t ni&#7879;u có bi&#7871;n ch&#7913;ng, nh&#432;
viêm th&#7853;n - b&#7875; th&#7853;n c&#7845;p và m&#7841;n tính, viêm bàng
quang n&#7863;ng tái phát; nhi&#7877;m khu&#7849;n &#273;&#432;&#7901;ng hô h&#7845;p,
nh&#432; viêm ph&#7893;i n&#7863;ng do vi khu&#7849;n, viêm ph&#7871; qu&#7843;n
- ph&#7893;i, áp xe ph&#7893;i; nhi&#7877;m khu&#7849;n ngo&#7841;i khoa,
nh&#432; áp xe b&#7909;ng, áp xe màng b&#7909;ng, nhi&#7877;m khu&#7849;n sau
ph&#7851;u thu&#7853;t; các nhi&#7877;m khu&#7849;n khác: Viêm m&#7911; màng ph&#7893;i,
nhi&#7877;m khu&#7849;n n&#7863;ng &#273;&#432;&#7901;ng ru&#7897;t.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>L&#432;u ý: C&#7847;n ti&#7871;n hành nuôi c&#7845;y và th&#7917; nghi&#7879;m
tính nh&#7841;y c&#7843;m c&#7911;a vi khu&#7849;n tr&#432;&#7899;c và trong
khi &#273;i&#7873;u tr&#7883;. C&#7847;n xét nghi&#7879;m ch&#7913;c n&#259;ng
th&#7853;n khi có ch&#7881; &#273;&#7883;nh. <o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ch&#7889;ng
ch&#7881; &#273;&#7883;nh<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Cefalotin ch&#7889;ng ch&#7881; &#273;&#7883;nh v&#7899;i ng&#432;&#7901;i
có ti&#7873;n s&#7917; d&#7883; &#7913;ng v&#7899;i kháng sinh nhóm
cephalosporin. <o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Th&#7853;n
tr&#7885;ng<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Vì &#273;ã th&#7845;y có ph&#7843;n &#7913;ng quá m&#7851;n chéo (bao
g&#7891;m s&#7889;c ph&#7843;n v&#7879;) gi&#7919;a nh&#7919;ng ng&#432;&#7901;i
b&#7879;nh d&#7883; &#7913;ng v&#7899;i các kháng sinh nhóm beta - lactam, nên
ph&#7843;i r&#7845;t th&#7853;n tr&#7885;ng và s&#7861;n sàng &#273;i&#7873;u
tr&#7883; s&#7889;c ph&#7843;n v&#7879; khi dùng cefalotin cho ng&#432;&#7901;i
tr&#432;&#7899;c &#273;ây &#273;ã b&#7883; d&#7883; &#7913;ng v&#7899;i
penicilin. Tuy nhiên, cefalotin ph&#7843;n &#7913;ng quá m&#7851;n chéo v&#7899;i
penicilin có t&#7927; l&#7879; th&#7845;p.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Th&#7853;n tr&#7885;ng khi dùng cefalotin cho ng&#432;&#7901;i suy th&#7853;n:
Có th&#7875; ph&#7843;i gi&#7843;m li&#7873;u. Dùng k&#7871;t h&#7907;p v&#7899;i
gentamicin và các aminoglycosid khác có nguy c&#417; t&#259;ng nhi&#7877;m
&#273;&#7897;c th&#7853;n. C&#7847;n theo dõi ch&#7913;c n&#259;ng th&#7853;n
và th&#7901;i gian &#273;ông máu, nh&#7845;t là trong th&#7901;i gian &#273;i&#7873;u
tr&#7883; cefalotin dài ngày và li&#7873;u cao.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Dùng cefalotin dài ngày có th&#7875; làm phát tri&#7875;n quá m&#7913;c
các ch&#7911;ng không nh&#7841;y c&#7843;m. C&#7847;n theo dõi ng&#432;&#7901;i
b&#7879;nh c&#7849;n th&#7853;n. N&#7871;u b&#7883; b&#7897;i nhi&#7877;m, ph&#7843;i
ng&#7915;ng thu&#7889;c.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Ðã có thông báo viêm &#273;&#7841;i tràng màng gi&#7843; khi s&#7917;
d&#7909;ng các kháng sinh ph&#7893; r&#7897;ng, vì v&#7853;y c&#7847;n ph&#7843;i
quan tâm ch&#7849;n &#273;oán b&#7879;nh này và &#273;i&#7873;u tr&#7883; b&#7857;ng
metronidazol cho ng&#432;&#7901;i b&#7883; &#7881;a ch&#7843;y n&#7863;ng liên
quan t&#7899;i s&#7917; d&#7909;ng kháng sinh. <o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Th&#7901;i
k&#7923; mang thai<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Cefalotin &#273;&#432;&#7907;c dùng &#7903; m&#7885;i giai &#273;o&#7841;n
mang thai và th&#432;&#7901;ng &#273;&#432;&#7907;c xem là s&#7917; d&#7909;ng
an toàn trong khi mang thai.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Không có thông báo nào v&#7873; m&#7889;i liên quan gi&#7919;a s&#7917;
d&#7909;ng cefalotin v&#7899;i các khuy&#7871;t t&#7853;t b&#7849;m sinh ho&#7863;c
&#273;&#7897;c tính trên tr&#7867; s&#417; sinh.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Th&#7901;i
k&#7923; cho con bú<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Cefalotin bài ti&#7871;t qua s&#7919;a m&#7865; &#7903; n&#7891;ng
&#273;&#7897; th&#7845;p. N&#7891;ng &#273;&#7897; này không có tác &#273;&#7897;ng
trên tr&#7867; &#273;ang bú s&#7919;a m&#7865;, nh&#432;ng c&#7847;n quan tâm
khi th&#7845;y tr&#7867; b&#7883; &#7881;a ch&#7843;y, t&#432;a và n&#7893;i
ban.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Tác d&#7909;ng
không mong mu&#7889;n (ADR)<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Ban da và &#273;au t&#7841;i ch&#7895; tiêm là nh&#7919;ng ADR
th&#432;&#7901;ng g&#7863;p nh&#7845;t.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><i><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Th&#432;&#7901;ng g&#7863;p, ADR &gt; 1/100<o:p></o:p></span></i></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Toàn thân: Ðau t&#7841;i ch&#7895; tiêm b&#7855;p, &#273;ôi khi b&#7883;
chai c&#7913;ng.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Tiêu hóa: &#7880;a ch&#7843;y.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Máu: T&#259;ng b&#7841;ch c&#7847;u &#432;a eosin, bi&#7871;n ch&#7913;ng
ch&#7843;y máu.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Da: Ban da d&#7841;ng s&#7847;n.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><i><span
lang=DE style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana;mso-ansi-language:DE'>Ít g&#7863;p, 1/1000 &lt; ADR &lt;
1/100<o:p></o:p></span></i></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Toàn thân: S&#7889;t.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Da: N&#7893;i mày &#273;ay.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><i><span
lang=DE style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;
font-family:Verdana;mso-ansi-language:DE'>Hi&#7871;m g&#7863;p, ADR &lt; 1/1000<o:p></o:p></span></i></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Toàn thân: Ph&#7843;n &#7913;ng gi&#7889;ng b&#7879;nh
huy&#7871;t thanh và ph&#7843;n v&#7879;.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Máu: Gi&#7843;m b&#7841;ch c&#7847;u trung tính,
gi&#7843;m ti&#7875;u c&#7847;u, thi&#7871;u máu tan máu, th&#7917; nghi&#7879;m
Coombs d&#432;&#417;ng tính.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Tiêu hóa: Viêm &#273;&#7841;i tràng màng gi&#7843;,
bu&#7891;n nôn và nôn.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Th&#7853;n: Nhi&#7877;m &#273;&#7897;c th&#7853;n
có t&#259;ng t&#7841;m th&#7901;i urê huy&#7871;t/creatinin, viêm th&#7853;n k&#7869;.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Gan: Vàng da &#7913; m&#7853;t, t&#259;ng nh&#7865;
AST, ALT.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Khác: Ðau kh&#7899;p và b&#7879;nh n&#7845;m <i>Candida</i>.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;letter-spacing:-.1pt;mso-ansi-language:DE'>ADR có th&#7875; có liên
quan t&#7899;i li&#7873;u cao: C&#417;n co gi&#7853;t và nh&#7919;ng d&#7845;u
hi&#7879;u nhi&#7877;m &#273;&#7897;c h&#7879; th&#7847;n kinh trung
&#432;&#417;ng, &#273;&#7863;c bi&#7879;t &#7903; ng&#432;&#7901;i suy th&#7853;n;
viêm t&#297;nh m&#7841;ch huy&#7871;t kh&#7889;i sau khi tiêm truy&#7873;n t&#297;nh
m&#7841;ch.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%'><span lang=DE
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>H&#432;&#7899;ng d&#7851;n cách x&#7917; trí ADR<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>V&#7899;i ng&#432;&#7901;i suy th&#7853;n, có th&#7875;
ph&#7843;i gi&#7843;m li&#7873;u dùng (xin &#273;&#7885;c m&#7909;c &quot;Li&#7873;u
l&#432;&#7907;ng&quot;).<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>C&#7847;n theo dõi ch&#7913;c n&#259;ng th&#7853;n
và th&#7901;i gian &#273;ông máu, nh&#7845;t là khi &#273;i&#7873;u tr&#7883;
dài ngày và li&#7873;u cao. Ng&#7915;ng cefalotin trong tr&#432;&#7901;ng h&#7907;p
d&#7883; &#7913;ng ho&#7863;c ph&#7843;n &#7913;ng quá m&#7851;n nghiêm tr&#7885;ng,
c&#7847;n ti&#7871;n hành &#273;i&#7873;u tr&#7883; h&#7895; tr&#7907; (duy trì
thông khí và s&#7917; d&#7909;ng epinephrin, oxygen, tiêm t&#297;nh m&#7841;ch
glucocorticosteroid). Các tr&#432;&#7901;ng h&#7907;p b&#7883; viêm &#273;&#7841;i
tràng màng gi&#7843; th&#7875; nh&#7865;, th&#432;&#7901;ng ch&#7881; c&#7847;n
ng&#7915;ng thu&#7889;c. Các tr&#432;&#7901;ng h&#7907;p v&#7915;a và n&#7863;ng,
c&#7847;n dùng các d&#7883;ch và các ch&#7845;t &#273;i&#7879;n gi&#7843;i, b&#7893;
sung protein và &#273;i&#7873;u tr&#7883; b&#7857;ng thu&#7889;c kháng khu&#7849;n
có hi&#7879;u l&#7921;c v&#7899;i <i>C. difficile</i> (dùng metronidazol, không
dùng vancomycin).<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
lang=DE style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana;
mso-ansi-language:DE'>Li&#7873;u l&#432;&#7907;ng và cách dùng<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Ng&#432;&#7901;i l&#7899;n: Li&#7873;u thông
th&#432;&#7901;ng tiêm b&#7855;p hay tiêm t&#297;nh m&#7841;ch: 500 mg &#273;&#7871;n
1 g, cách nhau 4 - 6 gi&#7901;/l&#7847;n tùy theo m&#7913;c &#273;&#7897; nhi&#7877;m
khu&#7849;n. Tr&#432;&#7901;ng h&#7907;p nhi&#7877;m khu&#7849;n n&#7863;ng,
nên dùng li&#7873;u 2 g tiêm t&#297;nh m&#7841;ch, 4 l&#7847;n/ngày. N&#7871;u
b&#7879;nh &#273;e d&#7885;a gây t&#7917; vong, có th&#7875; t&#259;ng li&#7873;u
&#273;&#7871;n 12 g/ngày (2 g, cách nhau 4 gi&#7901; 1 l&#7847;n). <o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Tr&#7867; em: Li&#7873;u thông th&#432;&#7901;ng
80 - 160 mg/kg/ngày chia làm 3 - 4 l&#7847;n. <o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span lang=DE
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana;mso-ansi-language:DE'>Ng&#432;&#7901;i l&#7899;n b&#7883; suy th&#7853;n:
Li&#7873;u kh&#7903;i &#273;&#7847;u là 1 - 2 g tiêm t&#297;nh m&#7841;ch. Sau
&#273;ó ch&#7881;nh li&#7873;u ti&#7871;p theo tùy theo &#273;&#7897; thanh th&#7843;i
creatinin c&#7911;a ng&#432;&#7901;i b&#7879;nh, li&#7873;u duy trì t&#7889;i
&#273;a nh&#432; sau:<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:447.75pt;
 height:120pt'>
 <v:imagedata src="Cefalotin_files/image001.png" o:title="untitled"/>
</v:shape><![endif]--><![if !vml]><img width=597 height=160
src="image002-14.jpg" tppabs="http://www.vietstarse.com/duocthu/Documents/Cefalotin_files/image002.jpg" v:shapes="_x0000_i1025"><![endif]><o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>D&#7921;
phòng trong ph&#7851;u thu&#7853;t nhi&#7877;m khu&#7849;n ho&#7863;c có ti&#7873;m
n&#259;ng nhi&#7877;m khu&#7849;n:<o:p></o:p></span></p>

<p class=MsoBlockText style='margin:0in;margin-bottom:.0001pt;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ng&#432;&#7901;i
l&#7899;n: Li&#7873;u thông th&#432;&#7901;ng 1 - 2 g tiêm t&#297;nh m&#7841;ch
30 - 60 phút tr&#432;&#7899;c khi ph&#7851;u thu&#7853;t và 1 - 2 g cách 6 gi&#7901;
1 l&#7847;n sau ph&#7851;u thu&#7853;t. Ð&#7889;i v&#7899;i ph&#7851;u thu&#7853;t
kéo dài, có th&#7875; cho trong khi ph&#7851;u thu&#7853;t 1 - 2 g.<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Tr&#7867;
em: 20 - 30 mg/kg cùng kho&#7843;ng th&#7901;i gian nh&#432; &#7903; ng&#432;&#7901;i
l&#7899;n. D&#7921; phòng th&#432;&#7901;ng ng&#7915;ng trong vòng 24 gi&#7901;
sau ph&#7851;u thu&#7853;t.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Tiêm t&#297;nh m&#7841;ch: Hòa tan 1 g cefalotin trong 10 ml dung d&#7883;ch
natri clorid 0,9%, ho&#7863;c 10 ml glucose tiêm 5%, ho&#7863;c 10 ml n&#432;&#7899;c
c&#7845;t tiêm. Tiêm t&#7915; t&#7915; li&#7873;u 1 g cefalotin trong th&#7901;i
gian ít nh&#7845;t 5 phút. Viêm t&#7855;c t&#297;nh m&#7841;ch th&#432;&#7901;ng
x&#7843;y ra khi tiêm t&#297;nh m&#7841;ch cefalotin v&#7899;i li&#7873;u cao
h&#417;n 6 g m&#7895;i ngày, kéo dài quá 3 ngày.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Tiêm truy&#7873;n không liên t&#7909;c: Cách dùng này cho n&#7891;ng
&#273;&#7897; huy&#7871;t thanh r&#7845;t cao và có hi&#7879;u qu&#7843;. Li&#7873;u
thích h&#7907;p trong 24 gi&#7901; là 8 - 12 g, m&#7895;i l&#7847;n tiêm truy&#7873;n
2 g, 4 l&#7847;n ho&#7863;c 6 l&#7847;n/ngày. Hòa tan 2 g cefalotin trong 100
ml dung d&#7883;ch natri clorid tiêm 0,9% ho&#7863;c 100 ml glucose tiêm 5%.
Nên tiêm truy&#7873;n th&#7875; tích này trong th&#7901;i gian t&#7915; 30
&#273;&#7871;n 50 phút.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Tiêm b&#7855;p: Hòa tan l&#7885; thu&#7889;c 1 g trong 4 ml n&#432;&#7899;c
c&#7845;t tiêm. Chia th&#7875; tích này thành 2 li&#7873;u tiêm b&#7855;p, m&#7895;i
li&#7873;u là 0,5 g cefalotin trong 2,2 ml; c&#7847;n tiêm b&#7855;p sâu.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>T&#432;&#417;ng
tác thu&#7889;c<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Cefalotin có th&#7875; gây tr&#7903; ng&#7841;i cho vi&#7879;c &#273;o
n&#7891;ng &#273;&#7897; creatinin theo ph&#432;&#417;ng pháp Jaffé và có th&#7875;
cho giá tr&#7883; cao gi&#7843; t&#7841;o; nên nh&#7899; &#273;i&#7873;u này
khi ki&#7875;m tra ch&#7913;c n&#259;ng th&#7853;n. Cefalotin c&#361;ng cho k&#7871;t
qu&#7843; th&#7917; nghi&#7879;m Coombs tr&#7921;c ti&#7871;p d&#432;&#417;ng
tính gi&#7843; và có th&#7875; gây tr&#7903; ng&#7841;i cho ph&#7843;n &#7913;ng
máu chéo. N&#432;&#7899;c ti&#7875;u c&#7911;a ng&#432;&#7901;i b&#7879;nh
&#273;i&#7873;u tr&#7883; b&#7857;ng cefalotin có th&#7875; cho ph&#7843;n &#7913;ng
glucose d&#432;&#417;ng tính gi&#7843; v&#7899;i ph&#7843;n &#7913;ng kh&#7917;
&#273;&#7891;ng.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Dùng &#273;&#7891;ng th&#7901;i v&#7899;i thu&#7889;c gây &#273;&#7897;c
th&#7853;n, nh&#432; kháng sinh aminoglycosid (gentamicin) có th&#7875; làm
t&#259;ng nguy c&#417; t&#7893;n th&#432;&#417;ng th&#7853;n. C&#361;ng có ch&#7913;ng
c&#7913; t&#259;ng nhi&#7877;m &#273;&#7897;c th&#7853;n khi dùng v&#7899;i m&#7897;t
thu&#7889;c l&#7907;i ti&#7875;u quai nh&#432; furosemid, nh&#432;ng không th&#7875;
hi&#7879;n ch&#7855;c ch&#7855;n nh&#432; furosemid v&#7899;i cefaloridin.
Probenecid &#7913;c ch&#7871; bài ti&#7871;t efalotin &#7903; th&#7853;n. Có th&#7875;
có s&#7921; &#273;&#7889;i kháng gi&#7919;a cefalotin và các ch&#7845;t kìm khu&#7849;n.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Ð&#7897;
&#7893;n &#273;&#7883;nh và b&#7843;o qu&#7843;n<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Dung d&#7883;ch &#273;ã pha &#7893;n &#273;&#7883;nh trong th&#7901;i
gian t&#7915; 12 - 24 gi&#7901; &#7903; nhi&#7879;t &#273;&#7897; phòng và
&#273;&#7875; &#273;&#432;&#7907;c 96 gi&#7901; n&#7871;u b&#7843;o qu&#7843;n
trong t&#7911; l&#7841;nh; dung d&#7883;ch tiêm truy&#7873;n t&#297;nh m&#7841;ch
trong natri clorid tiêm 0,9% ho&#7863;c glucose tiêm 5% &#7893;n &#273;&#7883;nh
trong 24 gi&#7901; &#7903; nhi&#7879;t &#273;&#7897; phòng, &#7893;n &#273;&#7883;nh
trong 96 gi&#7901; trong t&#7911; l&#7841;nh ho&#7863;c &#7893;n &#273;&#7883;nh
trong 12 tu&#7847;n n&#7871;u làm &#273;óng b&#259;ng; sau khi làm &#273;óng
b&#259;ng, dung d&#7883;ch tan b&#259;ng có th&#7875; &#7893;n &#273;&#7883;nh
trong 24 gi&#7901; &#7903; nhi&#7879;t &#273;&#7897; phòng ho&#7863;c 96 gi&#7901;
trong t&#7911; l&#7841;nh.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>T&#432;&#417;ng
k&#7925;<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Ðã th&#7845;y cefalotin t&#432;&#417;ng k&#7925; v&#7899;i
aminoglycosid và nhi&#7873;u ch&#7845;t khác. Không tr&#7897;n l&#7851;n
cefalotin và aminoglycosid trong cùng l&#7885;/túi. T&#7911;a có th&#7875; x&#7843;y
ra &#7903; dung d&#7883;ch pH d&#432;&#7899;i 5.<o:p></o:p></span></p>

<p class=3 style='margin-top:0in;line-height:150%;mso-outline-level:1'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Quá li&#7873;u
và x&#7917; trí<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>Các tri&#7879;u ch&#7913;ng quá li&#7873;u bao g&#7891;m ph&#7843;n &#7913;ng
quá m&#7851;n th&#7847;n kinh c&#417;, co gi&#7853;t, &#273;&#7863;c bi&#7879;t
&#7903; ng&#432;&#7901;i suy th&#7853;n.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>X&#7917; trí quá li&#7873;u c&#7847;n cân nh&#7855;c &#273;&#7871;n kh&#7843;
n&#259;ng quá li&#7873;u c&#7911;a nhi&#7873;u lo&#7841;i thu&#7889;c, s&#7921;
t&#432;&#417;ng tác thu&#7889;c và d&#432;&#7907;c &#273;&#7897;ng h&#7885;c b&#7845;t
th&#432;&#7901;ng c&#7911;a ng&#432;&#7901;i b&#7879;nh.<o:p></o:p></span></p>

<p class=2 align=left style='text-align:left;line-height:150%'><span
style='font-size:9.0pt;mso-bidi-font-size:14.0pt;line-height:150%;font-family:
Verdana'>N&#7871;u có co gi&#7853;t, ng&#7915;ng ngay thu&#7889;c và có th&#7875;
dùng li&#7879;u pháp ch&#7889;ng co gi&#7853;t n&#7871;u có ch&#7881; &#273;&#7883;nh
v&#7873; lâm sàng. B&#7843;o v&#7879; &#273;&#432;&#7901;ng hô h&#7845;p, h&#7895;
tr&#7907; thông khí và truy&#7873;n d&#7883;ch. Theo dõi c&#7849;n th&#7853;n
và duy trì trong ph&#7841;m vi cho phép các d&#7845;u hi&#7879;u <span
style='letter-spacing:.1pt'>sinh t&#7891;n c&#7911;a ng&#432;&#7901;i b&#7879;nh,
các khí trong máu, các ch&#7845;t &#273;i&#7879;n gi&#7843;i trong huy&#7871;t
thanh v.v... N&#7871;u g&#7863;p quá li&#7873;u tr&#7847;m tr&#7885;ng, &#273;&#7863;c
bi&#7879;t &#7903; ng&#432;&#7901;i suy th&#7853;n, có th&#7875; ph&#7889;i h&#7907;p
th&#7849;m tách máu và truy&#7873;n máu, n&#7871;u &#273;i&#7873;u tr&#7883; b&#7843;o
t&#7891;n b&#7883; th&#7845;t b&#7841;i. Tuy nhiên, ch&#432;a có d&#7919; li&#7879;u
có giá tr&#7883; ch&#7913;ng minh cách &#273;i&#7873;u tr&#7883; này.<o:p></o:p></span></span></p>

<p class=cach0 align=left style='margin-top:0in;text-align:left;line-height:
150%'><span style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Thông
tin qui ch&#7871;<o:p></o:p></span></p>

<p class=MsoNormal align=left style='text-align:left;line-height:150%'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:Verdana'>Cefalotin
ph&#7843;i kê &#273;&#417;n và bán theo &#273;&#417;n.<o:p></o:p></span></p>

</div>

</body>


<!-- Mirrored from medicain.net/DUOC THU QUOC GIA/Cefalotin.htm by HTTrack Website Copier/3.x [XR&CO'2013], Tue, 25 Mar 2014 18:06:29 GMT -->
</html>
